Quick Answer
Xeris Biopharma Holdings, Inc. reported Stockholders Equity of $13.69 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $13.69M | +146.2% |
| 2024 | -$29.61M | -336.7% |
| 2023 | -$6.78M | -115.0% |
| 2022 | $45.19M | -52.6% |
| 2021 | $95.23M | +182.1% |
| 2020 | $33.76M | +133.9% |
| 2019 | $14.44M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$861.0K | +97.0% | +95.5% |
| June 30, 2025 | -$19.30M | -0.1% | +45.0% |
| March 31, 2025 | -$35.13M | -282.7% | -18.6% |
| December 31, 2024 | -$29.61M | -336.7% | -4.6% |
| September 30, 2024 | -$28.32M | -832.8% | -46.9% |
| June 30, 2024 | -$19.29M | -241.4% | -110.1% |
| March 31, 2024 | -$9.18M | -130.5% | -35.3% |
| December 31, 2023 | -$6.78M | -115.0% | -275.5% |
- Xeris Biopharma Holdings, Inc. showed an increase of +146.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Xeris Biopharma Holdings, Inc.’s stockholders equity has declined by 5.2% (from $14.44 million to $13.69 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: